Role of a p53 polymorphism in the development of human papilloma-virus- associated cancer

Nature

Volumn 393, Issue 6682, 1998, Pages 229-234

  Storey, Alan ^a   Thomas, Miranda ^b   Kalita, Ann ^c   Harwood, Catherine ^a   Gardiol, Daniela ^b   Mantovani, Fiamma ^b   Breuer, Judith ^d   Leigh, Irene M ^a   Matlashewski, Greg ^c   Banks, Lawrence ^b  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^c MCGILL UNIVERSITY   (Canada)

^d ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PROTEIN P53;

ARTICLE; CARCINOGENESIS; GENOTYPE; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN DEGRADATION; SKIN CANCER; UTERINE CERVIX CANCER; WART VIRUS;

ALLELES; ARGININE; CARCINOMA, SQUAMOUS CELL; DISEASE SUSCEPTIBILITY; DNA-BINDING PROTEINS; FEMALE; GENE DELETION; GENOTYPE; HETEROZYGOTE; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMORPHISM, GENETIC; REPRESSOR PROTEINS; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 7144250518     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/30400     Document Type: Article

References (48)

1. zur Hausen, H. & Schneider, A. in The Papovaviridae (eds Salzman, N. P. & Howley, P. M.) 245-263 (Plenum, New York, 1987).
2. Dyson, N., Howley, P. M., Münger, K. & Harlow, E. The human papillomavirus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243, 934-936 (1989).
3. Scheffner, M., Werness, B. A., Huibregste, J. M., Levine, A. J. & Howley, P. M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63, 1129-1136 (1990).
4. Werness, B. A., Levine, A. J. & Howley, P. M. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248, 76-79 (1990).
5. Crook, T., Wrede, D. & Vousden, K. H. p53 point mutation in HPV negative human cervical carcinoma cell lines. Oncogene 6, 873-875 (1991).
6. Scheffner, M., Münger, K., Byrne, J. C. & Howley, P. M. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc. Natl Acad. Sci. USA 88, 5523-5527 (1991).
7. Vogelstein, B. & Kinzler, K. W. p53 function and dysfunction. Cell 70, 523-526 (1992).
8. Medcalf, E. A. & Milner, J. Targeting and degradation of p53 by E6 of human papillomavirus type 16 is preferential for the 1620+ p53 conformation. Oncogene 8, 2847-2851 (1993).
9. Marston, N. J., Crook, T. & Vousden, K. H. Interaction of p53 with MDM2 is independent of E6 and does not mediate wild type transformation suppressor function. Oncogene 9, 2707-2716 (1994).
10. Thomas, M., Massimi, P., Jenkins, I. & Banks, L. HPV-18 E6 mediated inhibition of p53 binding activity is independent of E6 induced degradation. Oncogene 10, 261-268 (1995).
11. Matlashewski, G. J. et al. Primary structure polymorphism at amino acid residue 72 of human p53. Mol. Cell. Biol. 7, 961-963 (1987).
12. Birgander, R. et al. P53 polymorphisms and haplotypes in lung cancer. Carcinogenesis 16, 2233-2236 (1995).
13. Moreau, F. & Matlashewski, G. Molecular analysis of different allelic variants of wild-type human p53. Biochem. Cell Biol. 70, 1014-1019 (1992).
14. Crook, T., Ludwig, R. L., Marston, N., Willkomm, D. & Vousden, K. H. Sensitivity of p53 lysine mutants to ubiquitin-directed degradation targeted by human papillomavirus E6. Virology 217, 285-292 (1996).
15. Goldberg, A. The mechanism and function of ATP dependent proteases in bacterial and animal cells. Eur. J. Biochem. 203, 285-292 (1992).
16. Hershko, D. & Ciechanover, A. The ubiquitin system for protein degradation. Annu. Rev. Biochem. 61, 761-807 (1992).
17. Rock, K. et al. Inhibitors of the proteasome block degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78, 761-771 (1994).
18. Milner, J. & Medcalf, E. A. Cotranslation of activated mutant p53 with wild type drives the wild type p53 into the mutant conformation. Cell 65, 765-774 (1991).
19. Sakamoto, H., Lewis, M. S., Kodama, H., Appella, E. & Sakaguchi, K. Specific sequences from the carboxy terminus of human p53 gene product form anti-parallel tetramers in solution. Proc. Natl. Acad. Sci. USA 91, 8974-8978 (1994).
20. Androphy, E. J., Hubbert, N. L., Schiller, J. T. & Lowy, D. R. Identification ofthe HPV16 E6 protein from transformed mouse cells and human cervical carcinoma cell lines. EMBO J. 6, 989-992 (1987).
21. Butz, K. et al. Functional p53 protein in human papillomavirus-positive cancer cells. Oncogene 10, 927-936 (1995).
22. Fenteany, G. et al. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 268, 726-731 (1995).
23. Zhang, W., Hu, G. & Deisseroth, A. Polymorphism at codon 72 of the p53 gene in human acute myelogenous leukemia. Gene 117, 271-275 (1992).
24. Vogan, K. et al. Absence of p53 gene mutations in primary neuroblastomas. Cancer Res. 53, 5269-5273 (1993).
25. Beckman, G. et al. Is p53 porymorphism maintained by natural selection? Hum. Hered. 44, 266-270 (1994).
26. Weston, A. et al. Determination of the allelic frequencies of an L-myc and a p53 polymorphism in human lung cancer. Carcinogenesis 14, 583-587 (1994).
27. Murata, M. et al. Analysis of a germ line polymorphism of the p53 gene in lung cancer patients: discrete results with smoking history. Carcinogenesis 17, 261-264 (1996).
28. Kawajiri, K., Nakachi, K., Imai, K., Watanabe, J. & Hayashi, S. Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis 14, 1085-1089 (1993).
29. Jin, X. et al. Higher lung cancer risk for young African-Americans with the Pro/Pro p53 genotype. Carcinogenesis 16, 2205-2208 (1995).
30. Purdie, K. et al. Malignant transformation of cutaneous lesions in renal allograft patients: a role for human papillomavirus. Cancer Res. 53, 5328-5333 (1993).
31. Boyle, J., Briggs, J. D., Mackie, R. M., Junor, B. J. R. & Aitchison, T. C. Cancer, warts and sunshine in renal transplant patients. Cancer Res. 53, 5328-5333 (1993).
32. Blessing, K. et al. Histopathology of skin lesions in renal allograft recipients - an assessment of viral features and dysplasia. Histopathology 14, 129-139 (1989).
33. Benton, E. C. et al. in Immunodeficiency and the Skin (eds Fritsch, P., Schuler, G. & Hintner, H.) 168-177 (Karger, Basel, 1989).
34. Glover, M. T., Proby, C. M. & Leigh, I. M. Skin cancer in renal transplant patients. Cancer Bull. 45, 220-224 (1993).
35. Shamanin, V. et al. Specific types of human papillomavirus found in benign proliferations and carcinomas of the skin in immunosuppressed patients. Cancer Res. 54, 4610-4613 (1994).
36. Berkhout, R. J. M. et al. Detection and typing of epidermodysplasia verruciformis-associated human papillomavirus types in cutaneous cancers from renal transplant recipients. J. Clin. Microbiol. 33, 690-695 (1995).
37. Shamanin, V. et al. Human papillomavirus infections in non melanoma skin cancer patients from renal transplant recipients and nonimmunosuppressed patients. J. Natl Canc. Inst. 88, 802-811 (1996).
38. Li, X. & Coffino, P. High-risk human papillomavirus E6 has two distinct binding sites within p53, of which only one determines degradation. J. Virol. 70, 4509-4516 (1996).
39. Walker, K. K. & Levine, A. J. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc. Natl Acad. Sci. USA 93, 15335-15340 (1996).
40. Sakamuro, D., Sabbatini, P., White, E. & Prendergast, G. C. The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene 15, 887-898 (1997).
41. Yu, H. et al. Structural basis for the binding of proline-rich peptides to SH3 domains. Cell 76, 933-945 (1994).
42. Sun, X.-F. et al. A novel p53 germline alteration identified in a late onset breast cancer kindred. Oncogene 13, 407-411 (1996).
43. Chittenden, T. et al. A conserved domain in bak, distinct from BH1 and BH2, mediates cell death and protein binding functions. EMBO J. 14, 5589-5596 (1995).
44. Banks, L. Matlashewski, G. & Crawford, L. Isolation of human p53 specific monoclonal antibodies and their use in the study of human p53 expression. Eur. J. Biochem. 159, 529-534 (1986).
45. Manos, M. M. et al. The use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. Cancer Cells 7, 209-214 (1989).
46. Snijders, P. J. et al. The use of general primers in the polymerase chain reaction permits the detection of a broad spectrum of human papillomavirus genotypes. J. Gen. Virol. 71, 173-181 (1990).
47. Shamanin, V., Delius, H. & de Villiers, E.-M. Development of a broad spectrum PCR assay for papillomaviruses and its application in screening lung cancer biopsies. J. Gen. Virol. 75, 1149-1156 (1994).
48. Chan, S.-Y., Delius, H., Halpern, A. L. & Bernard, H.-U. Analysis of genomic sequences of 95 papillomavirus types: uniting typing phylogeny and taxonomy. J. Virol. 69, 3074-3083 (1995).